18.02

4.05% -0.76

After Hours: 18.25 0.23 +1.28%

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $18.02, with a volume of 1.07M. It is down -4.05% in the last 24 hours and up +5.20% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Previous Close:

$18.78

Open:

$18.61

24h Volume:

1.07M

Relative Volume:

0.70

Market Cap:

$1.29B

Revenue:

Net Income/Loss:

$-230.32M

P/E Ratio:

-5.1108

EPS:

-3.5259

Net Cash Flow:

$-196.04M

1W Performance:

-3.12%

1M Performance:

+5.20%

6M Performance:

+82.20%

1Y Performance:

-50.99%

1-Day Range:

$17.87

$19.02

1-Week Range:

$17.84

$19.73

52-Week Range:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

130

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLTX Moonlake Immunotherapeutics	18.02	1.35B	0	-230.32M	-196.04M	-3.5259
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Upgrade	Wolfe Research	Underperform → Outperform
Mar-19-26	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Jan-15-26	Downgrade	Goldman	Neutral → Sell
Jan-09-26	Upgrade	BTIG Research	Neutral → Buy
Nov-03-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-01-25	Downgrade	Goldman	Buy → Neutral
Sep-30-25	Downgrade	Citigroup	Buy → Neutral
Sep-30-25	Downgrade	Wolfe Research	Outperform → Underperform
Sep-29-25	Downgrade	BTIG Research	Buy → Neutral
Sep-29-25	Downgrade	Jefferies	Buy → Hold
Sep-29-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-29-25	Downgrade	Stifel	Buy → Hold
Jul-28-25	Initiated	Rothschild & Co Redburn	Neutral
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Jan-17-25	Upgrade	Goldman	Neutral → Buy
Nov-05-24	Resumed	Wedbush	Outperform
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-02-24	Initiated	Goldman	Neutral
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

10:53 AM

H.C. Wainwright reiterates Moonlake stock rating on HS potential By Investing.com - Investing.com Australia

10:53 AM

Apr 14, 2026

Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention - TipRanks

Apr 14, 2026

Insider Sell: CEO Santos da Silva Jorge Sells 150,000 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus

Apr 14, 2026

MoonLake Immunotherapeutics Chief Executive Officer Sold Shares Worth Over $2.7M - TradingView — Track All Markets

Apr 14, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares - Stock Titan

Apr 14, 2026

Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Apr 14, 2026

Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics - TipRanks

Apr 14, 2026

MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN

Apr 14, 2026

Apr 13, 2026

MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal

Apr 13, 2026